GlassScriptPhysician profile
Erin Coppock
NPI 1467100990
$3,718.07
in general payments reported to CMS, 2019-2025
29 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $819 · 2024: $1,103 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.64 |
| Education | $162.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $867.83 | 2022-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $579.78 | 2023-2025 | Dupixent |
| United Therapeutics Corporation | $251.11 | 2023-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $194.48 | 2022-2025 | Opsumit, Uptravi |
| Jazz Pharmaceuticals INC. | $173.63 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $167.68 | 2023-2025 | Zerbaxa, Winrevair, Dificid |
| Amgen INC. | $158.81 | 2022-2025 | Tezspire |
| Glaxosmithkline, LLC. | $156.37 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Genzyme Corporation | $133.77 | 2024 | |
| Insmed, INC. | $124.51 | 2024-2025 | Arikayce |
| Grifols USA, LLC | $108.54 | 2022-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $103.21 | 2022-2024 | Yupelri |
| Electromed, INC. | $74.56 | 2023-2024 | Smartvest |
| Sanofi-Aventis U.S. LLC | $67.99 | 2024 | |
| Philips North America LLC | $66.14 | 2023-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $65.43 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $63.27 | 2024-2025 | Glassia, Aralast |
| Avadel Cns Pharmaceuticals, LLC | $58.51 | 2024-2025 | Lumryz |
| Harmony Biosciences LLC | $53.93 | 2024-2025 | |
| Itamar Medical INC | $38.84 | 2023-2024 | Watchpatone |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.12 | 2024 | Ofev |
| Verona Pharma, INC. | $30.58 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $30.02 | 2023 | Inspire |
| Csl Behring | $21.67 | 2023 | Hizentra |
| Mallinckrodt Hospital Products INC. | $21.48 | 2024 | Acthar |
| Azurity Pharmaceuticals, INC. | $20.61 | 2025 | Alvesco |
| Shionogi INC | $18.05 | 2023 | Fetroja |
| Genentech USA, INC. | $15.50 | 2024 | Xolair |
| Abbvie INC. | $13.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Coppock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.